Founded in 2015, New Horizon Health Limited is a pioneer and market leader in China's cancer screening market. The company is dedicated to the innovation, development, and commercialization of screening and early detection tests for high-incidence cancers. Its mission is to advance innovations in life sciences and to reduce the mortality rate of cancer by providing effective and user-friendly screening solutions. The company's key products include ColoClear®, a non-invasive multi-target FIT-DNA test for colorectal cancer screening, and Pupu Tube®, a self-applied FIT screening test. New Horizon Health was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 6606.HK) in February 2021.

Founded in

China